NYSE:JNJPharmaceuticals
How J&J’s 2026 Sales and EPS Outlook At Johnson & Johnson (JNJ) Has Changed Its Investment Story
Earlier this week, Johnson & Johnson reported fourth-quarter 2025 and full-year results showing sales of US$24.56 billion for the quarter and US$94.19 billion for the year, alongside 2026 guidance that targets operational sales of about US$100 billion and adjusted earnings per share of US$11.43–US$11.63.
The updates highlighted how therapies such as Darzalex and Tremfya, together with growth in the MedTech franchise and a deep pipeline, are underpinning the company’s confidence despite...